 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

GAITHERSBURG, Md., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Louis J. Aronne, Founder and Director of...

Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 59th Annual Meeting of the European Association for the Study of Diabetes

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Altimmune announces completion of dosing in Phase 2 MOMENTUM trial

Top-line 48-week results from the trial expected Q4 2023GAITHERSBURG, Md., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today...

Altimmune Announces Completion of Dosing in the Phase 2 MOMENTUM Trial of Pemvidutide in Subjects with Obesity or Overweight

Tower Research Capital LLC TRC reduced its stake in shares of Altimmune, Inc. (NASDAQ:ALT  Free Report) by 31.4% in the 1st quarter, according to its most recent Form 13F filing with the...

Tower Research Capital LLC TRC Has $85,000 Position in Altimmune, Inc. (NASDAQ:ALT)

GAITHERSBURG, Md., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Companys management team will participate and be available for 1x1 meetings at the following investor conferences: Wells Fargo 2023 ...

Altimmune to Participate at Two Upcoming Investor Conferences

Altimmune management to meet with B. Riley

Key Insights Institutions' substantial holdings in Altimmune implies that they have significant influence over the...

Altimmune, Inc.'s (NASDAQ:ALT) latest 12% decline adds to one-year losses, institutional investors may consider drastic measures

Altimmune, Inc. (NASDAQ:ALT  Get Free Report) has earned a consensus rating of Moderate Buy from the seven brokerages that are currently covering the company, Marketbeat.com...

Altimmune, Inc. (NASDAQ:ALT) Receives $24.57 Average PT from Analysts

Altimmune (NASDAQ:ALT Free Report) had its target price lowered by HC Wainwright from $50.00 to $15.00 in a research report released on Monday morning, Marketbeat reports. The firm currently has a buy rating on the stock. HC Wainwright also issued estimates for Altimmunes Q3 2023 earnings at ($0.36...

Altimmune (NASDAQ:ALT) PT Lowered to $15.00 at HC Wainwright

Altimmune (NASDAQ:ALT  Free Report) had its price target trimmed by B. Riley from $20.00 to $15.00 in a report released on Friday, Benzinga reports. The brokerage currently has a buy rating on...

Altimmune (NASDAQ:ALT) PT Lowered to $15.00 at B. Riley

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Watchers	24,743
52-Wk Low	$2.34
52-Wk High	$17.17

Market Cap	$132.24M
Volume (M)	7,161.00
52-Wk High	$17.17
52-Wk Low	$2.34

ALT Altimmune Inc

About

Feed

News

Sentiment

Earnings

Fundamentals